1
|
Lim JY, Lee CL, Kim GH, Bang YJ, Rhim JW, Yoon KS. Using lactic acid bacteria and packaging with grapefruit seed extract for controlling Listeria monocytogenes growth in fresh soft cheese. J Dairy Sci 2020; 103:8761-8770. [PMID: 32713695 DOI: 10.3168/jds.2020-18349] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2020] [Accepted: 05/13/2020] [Indexed: 11/19/2022]
Abstract
Various cheese products are involved in outbreaks of listeriosis worldwide due to high consumption and prolonged refrigerated storage. The objective of this study was to determine the efficacy of using lactic acid bacteria and packaging with grapefruit seed extract (GSE) for controlling Listeria monocytogenes growth in soft cheese. Leuconostoc mesenteroides and Lactobacillus curvatus isolated from kimchi were used as a starter culture to make a soft cheese, which was inoculated with a cocktail strain of L. monocytogenes. The soft cheese was packed with low-density polyethylene, biodegradable polybutylene adipate-co-terephthalate (PBAT), low-density polyethylene with GSE, or PBAT with GSE and stored at 10°C and 15°C. Leuconostoc mesenteroides (LcM) better inhibited the growth of L. monocytogenes than Lb. curvatus. The PBAT with GSE film showed the best control for the growth of L. monocytogenes. When both LcM and PBAT with GSE were applied to the soft cheese, the growth of L. monocytogenes was inhibited significantly more than the use of LcM or PBAT with GSE alone. In all test groups, water activity, pH, and moisture on a fat-free basis decreased, and titratable acidity increased compared with the control group. These results suggest that LcM isolated from kimchi and PBAT with GSE packaging film can be used as a hurdle technology to lower the risk of L. monocytogenes in soft cheese at the retail market.
Collapse
Affiliation(s)
- J Y Lim
- Department of Food and Nutrition, College of Human Ecology, Kyung Hee University, Seoul 02447, Republic of Korea
| | - C L Lee
- Department of Food and Nutrition, College of Human Ecology, Kyung Hee University, Seoul 02447, Republic of Korea
| | - G H Kim
- Department of Food and Nutrition, College of Human Ecology, Kyung Hee University, Seoul 02447, Republic of Korea
| | - Y J Bang
- Department of Food and Nutrition, College of Human Ecology, Kyung Hee University, Seoul 02447, Republic of Korea
| | - J W Rhim
- Department of Food and Nutrition, College of Human Ecology, Kyung Hee University, Seoul 02447, Republic of Korea
| | - K S Yoon
- Department of Food and Nutrition, College of Human Ecology, Kyung Hee University, Seoul 02447, Republic of Korea.
| |
Collapse
|
2
|
Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung H, Muro K, Gökkurt E, Mansoor W, McDermott R, Schacham-Shmueli E, Chen X, Kang SP, Mayo C, Ohtsu A, Fuchs C. KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy208.004] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
3
|
Bang YJ, Giaccone G, Im SA, Oh DY, Bauer TM, Nordstrom JL, Li H, Chichili GR, Moore PA, Hong S, Stewart SJ, Baughman JE, Lechleider RJ, Burris HA. First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. Ann Oncol 2017; 28:855-861. [PMID: 28119295 DOI: 10.1093/annonc/mdx002] [Citation(s) in RCA: 158] [Impact Index Per Article: 22.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2016] [Indexed: 12/26/2022] Open
Abstract
Background Margetuximab is an anti-HER2 antibody that binds with elevated affinity to both the lower and higher affinity forms of CD16A, an Fc-receptor important for antibody dependent cell-mediated cytotoxicity (ADCC) against tumor cells. A Phase 1 study was initiated to evaluate the toxicity profile, maximum tolerated dose (MTD), pharmacokinetics, and antitumor activity of margetuximab in patients with HER2-overexpressing carcinomas. Patients and methods Patients with HER2-positive breast or gastric cancer, or other carcinomas that overexpress HER2, for whom no standard therapy was available, were treated with margetuximab by intravenous infusion at doses of 0.1-6.0 mg/kg for 3 of every 4 weeks (Regimen A) or once every 3 weeks (10-18 mg/kg) (Regimen B). Results Sixty-six patients received margetuximab (34 patients for Regimen A and 32 patients for Regimen B). The MTD was not reached for either regimen. Treatment was well-tolerated, with mostly Grade 1 and 2 toxicities consisting of constitutional symptoms such as pyrexia, nausea, anemia, diarrhea, and fatigue. Among 60 response-evaluable patients, confirmed partial responses and stable disease were observed in 7 (12%) and 30 (50%) patients, respectively; 26 (70%) of these patients had received prior HER2-targeted therapy. Tumor reductions were observed in over half (18/23, 78%) of response-evaluable patients with breast cancer including durable (>30 weeks) responders. Ex vivo analyses of patient peripheral blood mononuclear cell samples confirmed the ability of margetuximab to support enhanced ADCC compared with trastuzumab. Conclusions Margetuximab was well-tolerated and has promising single-agent activity. Further development efforts of margetuximab as single agent and in combination with other therapeutic agents are ongoing. Trial Registration ID NCT01148849.
Collapse
Affiliation(s)
- Y J Bang
- Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea
| | - G Giaccone
- Department of Medical Oncology, National Cancer Institute, Bethesda, MD, USA
| | - S A Im
- Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea
| | - D Y Oh
- Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea
| | - T M Bauer
- Department of Drug Development, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, USA
| | | | - H Li
- MacroGenics, Inc, Rockville, Maryland 20850, USA
| | - G R Chichili
- MacroGenics, Inc, Rockville, Maryland 20850, USA
| | - P A Moore
- MacroGenics, Inc, Rockville, Maryland 20850, USA
| | - S Hong
- MacroGenics, Inc, Rockville, Maryland 20850, USA
| | - S J Stewart
- Departamento de Física, Facultad de Ciencias Exactas, UNLP, IFLP-CONICET C.C.No. 67, 1900 La Plata, Argentina
| | | | | | - H A Burris
- Department of Drug Development, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, USA
| |
Collapse
|
4
|
Reck M, Bang YJ, Goff L, Wasserstrom H, Yang J, Mi G, Karasarides M. Multizentrische, offene Phase 1 Studie mit Ramucirumab plus Durvalumab bei Patienten mit inoperablem lokal fortgeschrittenen oder metastasierten Adenokarzinom des Magens oder gastrooesophagealen Übergangs (G/GEJ), nichtkleinzelligem Lungenkarzinom (NCSLC) oder hepatozellulärem Karzinom (HCC). Pneumologie 2017. [DOI: 10.1055/s-0037-1598341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- M Reck
- Lungenclinic Großhansdorf, Airway Research Center North (Arcn), Member of the German Center for Lung Research (Dzl)
| | - YJ Bang
- Seoul National University Hospital, Seoul
| | - L Goff
- Vanderbilt-ingram Cancer Center, Nashville
| | | | - J Yang
- Eli Lilly and Company, Bridgewater
| | - G Mi
- Eli Lilly and Company, Indianapolis
| | | |
Collapse
|
5
|
Oh DY, Kim MR, Choi IS, Joh YH, Kim BS, Kim DY, Kim JH, Lee SH, Kim TY, Heo DS, Bang YJ, Kim NK. Discrepancies of the Values on the Withholding Futile Interventions between Physician and Family Members of Terminal Cancer Patients. Cancer Res Treat 2015; 33:350-6. [PMID: 26680807 DOI: 10.4143/crt.2001.33.4.350] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
PURPOSE To analyze the controversies surrounding therapeutic decision-making and the withholding of life- sustaining treatments, values held concerning therapeutic interventions of terminal cancer patients are compared between physicians and family members. MATERIALS AND METHODS 42 advanced or terminal stage cancer patients were enrolled for the study. The questionnaires were administered to the duty doctor and the family of the patients. Questions included whether to use new agents with a 15% partial efficacy and whether to use opioid analgesics, intravenous nutrition, a feeding tube, antibiotics, and hemodialysis. Additionally, we asked about the administration of CPR, ventilator application, and euthanasia. If the family permitted, the same questionnaires were given to the patients. RESULTS Of the 42 cases, 5 families refused to answer the questionnaire. Of the available 37 families, only 5 families permitted access to the patients. Of the 5 patients, 2 patients refused the questionnaire. Only 67.6% and 8.1% of families and the patients clearly understood the stage of cancer. The use of a new agent was accepted by 45.2% of the physicians and 45.9% of the families. The rankings of the acceptance of treatment in the physicians and in the families were similar. The concordance rate between the physicians and the families was lowest on ventilator application and CPR. 31% of the physicians and 43.2% of the families agreed on the issue of euthanasia. CONCLUSION Values held on issues like therapeutic decision-making and the withholding of life-sustaining treatments in terminal cancer patients are discordant between physicians and family members. In order to resolve controversies on the role of physicians in end-of-life decisions, the values of physicians as well as patients and their family members should be considered in the final decision-making process.
Collapse
|
6
|
Kim BS, Oh DY, Joh YH, Kim DY, Kim JH, Lee SH, Lee DH, Kim TY, Heo DS, Bang YJ, Kim NK. Efficacy of Low-dose Paclitaxel and Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer. Cancer Res Treat 2015; 33:469-73. [PMID: 26680824 DOI: 10.4143/crt.2001.33.6.469] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
PURPOSE To evaluate the efficacy and toxicity of combination chemotherapy with low-dose paclitaxel and cisplatin in patients with advanced non-small cell lung cancer. MATERIALS AND METHODS Chemotherapy-naive patients with unresectable, pathologically proven non-small cell lung cancer were eligible for inclusion in the study. Patients received paclitaxel (145 mg/m2 iv 3 hour D1) and cisplatin (60 mg/m2 iv D1) every 3 weeks. RESULTS Forty-two patients were enrolled between February 2000 and February 2001. The median age was 53.5 years. Patients with adenocarcinoma numbered 29, squamous cell carcinoma 7, large cell carcinoma 3, and undifferentiated carcinoma 3. Seventeen patients had stage IIIB, 19 had stage IV disease and the remaining 6 displayed recurred disease after previous surgical resection. Four patients terminated treatment early because of hypersensitivity (1) and severe emesis (3). Of the 38 evaluable patients, 14 had PR and the response rate was 36.8%. Among partial responders, 6 patients received additional chest radiation. The median duration of response was 47.9 weeks and the median overall survival was 54.0 weeks. Of the total 176 courses, 14 were delayed, 22 required dose reduction, and grade 3~4 neutropenia occurred in 5.6% of courses. Only one episode of neutropenic fever developed and there were no treatment- related mortalities. Other toxicities were generally mild. CONCLUSION The combination chemotherapy with low-dose paclitaxel and cisplatin was effective and tolerable in patients with advanced non-small cell lung cancer.
Collapse
|
7
|
Rajan N, Cuyun Carter G, Kaltenboeck A, Ivanova J, Liepa AM, San Roman A, Koh M, Ballal S, Birnbaum H, Cheng R, Chen JS, Bang YJ. HEALTH CARE RESOURCE USE AMONG ADVANCED GASTRIC CANCER PATIENTS IN TAIWAN AND SOUTH KOREA. Value Health 2014; 17:A734. [PMID: 27202630 DOI: 10.1016/j.jval.2014.08.100] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
- N Rajan
- Eli Lilly and Company, West Ryde, Australia
| | | | | | - J Ivanova
- Analysis Group, Inc., New York, NY, USA
| | - A M Liepa
- Eli Lilly and Company, Indianapolis, IN, USA
| | | | - M Koh
- Analysis Group, Inc., New York, NY, USA
| | - S Ballal
- ImClone Systems, Inc., New York, NY, USA
| | | | - R Cheng
- Eli Lilly and Company, Taipei, Taiwan
| | - J S Chen
- Linkou Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Tao-Yuan, Taiwan
| | - Y J Bang
- Seoul National University Hospital, Seoul, South Korea
| |
Collapse
|
8
|
Zamboni WC, Maruca LJ, Strychor S, Zamboni BA, Ramalingam S, Edwards RP, Kim JK, Bang YJ, Lee HY, Friedland DM, Stoller RG, Belani CP, Ramanathan RK. Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors. J Liposome Res 2010; 21:158-65. [DOI: 10.3109/08982104.2010.496085] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
9
|
Abstract
PURPOSE The optimal therapy for gastric lymphoma except MALToma has not yet been established. This study was undertaken to investigate whether gastric lymphoma can be managed effectively and safely with chemotherapy alone. PATIENTS AND METHODS A total of 58 patients (median age 56 years) with newly diagnosed gastric lymphoma between 1989--2001 at Seoul National University Hospital and who were initially managed with chemotherapy alone were evaluated. MALToma was excluded from the pathologic review. RESULTS All patients received initially anthracycline-containing chemotherapy. ECOG performance scale 0--1 was 88% and B symptoms were present in 41.4%. Diffuse large B cell type was the most common (74.1%). Stage IE, II1E accounted for 51.7% and II2E, IIIE, IV for 48.3%. The international prognostic index (IPI) of risk was low in 39.7%, low-intermediate in 22.4%, high-intermediate in 15.5% and high in 22.4%. The complete response rate after first-line chemotherapy was 71.4% and the partial response rate was 12.2%. (overall response rate: 83.6%). Among patients who did not reach the complete response, a further complete response was achieved by second-line chemotherapy including etoposide-based regimen. Ultimately, the maximum complete response rate by chemotherapy was 83.7% (92% in stage IE, II1E, 75% in stage II2E, IIIE, IV). Median overall survival was 47.4 months (84.7 months in stage IE, II1E, 32.5 months in stage II2E, IIIE, IV) and the 5-year survival rate was 46%. Bleeding as a complication occurred in 3 of 58 patients (5.6%) and these cases were controlled by embolization or conservative management. No perforation episode occurred and surgical intervention due to complication was not necessary. Organ preservation was possible in 57 of 58 patients (98%). The one gastrectomy was performed due to a partial clinical response to chemotherapy but the specimen showed pathologic CR. Multivariate analysis revealed that only IPI had a significant influence on survival. CONCLUSIONS Gastric lymphoma except MALToma can be managed effectively and safely with chemotherapy alone.
Collapse
Affiliation(s)
- Dy O H
- Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medecine, Seoul, Korea
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Lee JO, Lee KW, Oh DY, Kim JH, Im SA, Kim TY, Bang YJ. Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. Ann Oncol 2009; 20:1402-7. [PMID: 19502532 DOI: 10.1093/annonc/mdp010] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND We evaluated the efficacy and toxicity of combination chemotherapy with capecitabine and cisplatin (XP) in patients with metastatic hepatocellular carcinoma (HCC). PATIENTS AND METHODS From September 2003 to July 2007, we enrolled patients with HCC who had more than one measurable extrahepatic metastatic lesion. Patients received oral capecitabine (2000 mg/m(2)/day) with a schedule of 2 weeks on and 1 week off and cisplatin (60 mg/m(2)) on the first day of the 3-week cycle. RESULTS The study cohort consisted of 32 patients with a median age of 53 years. Overall response rate was 6.3% and disease control rate was 34.4%. The median time to progression (TTP) was 2.0 months [95% confidence interval (CI) 1.5-2.4] and the median overall survival (OS) time was 12.2 months (95% CI 6.5-17.8). The grade 3/4 hematologic toxic effects included thrombocytopenia (7.6%), neutropenia (4.3%) and anemia (2.1%). The grade 3/4 non-hematologic toxic effects included elevated hepatic aminotransferase (12.9%), jaundice (3.2%), mucositis (3.2%) and nausea (3.2%). There was no treatment-related mortality. CONCLUSIONS Based on the observed response rate and TTP, XP combination chemotherapy showed modest antitumor efficacy in patients with metastatic HCC as systemic first-line treatment. However, XP combination chemotherapy showed tolerable toxicity and demonstrated favorable OS time.
Collapse
Affiliation(s)
- J O Lee
- Department of Internal Medicine, Seoul National University Hospital, Chongno-gu, Seoul, Korea
| | | | | | | | | | | | | |
Collapse
|
11
|
Kim HJ, Keam B, Im S, Ham HS, Oh D, Kim J, Han WS, Kim T, Park IA, Bang YJ. Use of MDR1/ABCB1 single nucleotide polymorphism (SNP) as a prognostic factor for breast cancer patients receiving docetaxel + doxorubicin neoadjuvant chemotherapy. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
12
|
Kim YJ, Im SA, Kim HG, Oh SY, Lee KW, Choi IS, Oh DY, Lee SH, Kim JH, Kim DW, Kim TY, Kim SW, Heo DS, Yoon YB, Bang YJ. A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer. Ann Oncol 2008; 19:99-103. [PMID: 17846018 DOI: 10.1093/annonc/mdm439] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Optimal chemotherapy for advanced biliary tract cancer (BTC) is yet to be defined. We carried out this study to evaluate the efficacy and toxicity of combination chemotherapy with S-1 and cisplatin in metastatic or relapsed BTC. PATIENTS AND METHODS Patients with pathologically proven BTC were eligible. The chemotherapy regimen consisted of S-1 (40 mg/m(2) p.o. b.i.d. from D1-14) and cisplatin (60 mg/m(2) on D1), repeated every 3 weeks. RESULTS Fifty-one BTC patients (metastatic:relapsed = 37:14, Gall-bladder:intrahepatic bile ducts:extrahepatic bile ducts = 16:25:10) were enrolled from January 2005 to December 2006. Median age was 57 years (range, 31-71) and most patients had a good performance status. The overall response rate was 30% [95% confidence interval (CI), 17.3-42.7] and complete response was observed in two patients (4%), partial response in 13 (26%), stable disease in 21 (42%), and progressive disease in 9 (18%). With a median follow-up of 12.4 months, the median time to progression was 4.8 months (95% CI, 3.3-6.3) and median overall survival was 8.7 months (95% CI, 6.0-11.4). Major toxic effects were grade 3/4 neutropenia (8.9% of all cycles) and febrile neutropenia was observed in six cycles (2.7% of all cycles). CONCLUSION Combination chemotherapy with S-1 and cisplatin was a moderately effective outpatient-based regimen in BTC patients. Toxic effects were moderate but manageable.
Collapse
Affiliation(s)
- Y J Kim
- Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
León-Chong J, Lordick F, Kang YK, Park SR, Bang YJ, Sawaki A, Van Cutsem E, Stoss O, Jordan BW, Feyereislova A. HER2 positivity in advanced gastric cancer is comparable to breast cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.15057] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15057 Background: Accurate HER2 testing is required to identify patients eligible for treatment with trastuzumab (Herceptin®). HER2 positivity is reported as 6–35% in gastric cancer (GC). This range is due to small sample sets and differing methods of evaluation or scoring. A specific HER2-testing process was established for the Phase III ToGA trial, which is evaluating trastuzumab added to chemotherapy in HER2-positive advanced GC. Methods: A validation study was completed to standardise IHC (HercepTest™) and FISH (PharmDx™) protocols, and to establish a scoring system specific for GC (M Hofmann et al. ASCO Gastrointestinal Cancers Symposium 2006. Abstract no. 24). Tumour samples for ToGA were then centrally tested by both IHC and FISH to identify patients eligible for enrolment. Results: To date, 1024 tumour samples have been assessed (243 HER2 positive and 781 HER2 negative) giving an overall HER2-positivity rate of 23.7%. Both IHC and FISH results are available for 960 patients, with 87% concordance. Differences were largely due to FISH-positive cases that were IHC 0/1+. HER2 positivity differed significantly by histological subtype: 36% in intestinal, 7% in diffuse and 23% in mixed. HER2 positivity also varied according to the site of the tumour: 36% (8/22) for gastro-oesophageal junction tumours and 21% (60/291) for gastric tumours. Sample numbers were very small so these results must be treated with caution. The HER2- positivity rate was similar in specimens obtained by biopsy (168/689; 24%) and surgery (71/322; 22%). Conclusions: Using validated methodology and based on the large sample set from the ongoing ToGA trial, the HER2-positivity rate observed in advanced GC is as high as in breast cancer: ∼24%. The first efficacy data from ToGA are expected in 2009. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. León-Chong
- National Institute for Neoplastic Diseases, Surquillo, Peru; Munich University of Technology, Munich, Germany; Asan Medical Center, Seoul, Republic of Korea; National Cancer Center, Goyang, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea; Aichi Cancer Center, Nagoya, Japan; University Hospital Gasthuisberg, Leuven, Belgium; TARGOS Molecular Pathology GmbH, Kassel, Germany; F. Hoffmann-La Roche, Basel, Switzerland
| | - F. Lordick
- National Institute for Neoplastic Diseases, Surquillo, Peru; Munich University of Technology, Munich, Germany; Asan Medical Center, Seoul, Republic of Korea; National Cancer Center, Goyang, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea; Aichi Cancer Center, Nagoya, Japan; University Hospital Gasthuisberg, Leuven, Belgium; TARGOS Molecular Pathology GmbH, Kassel, Germany; F. Hoffmann-La Roche, Basel, Switzerland
| | - Y. K. Kang
- National Institute for Neoplastic Diseases, Surquillo, Peru; Munich University of Technology, Munich, Germany; Asan Medical Center, Seoul, Republic of Korea; National Cancer Center, Goyang, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea; Aichi Cancer Center, Nagoya, Japan; University Hospital Gasthuisberg, Leuven, Belgium; TARGOS Molecular Pathology GmbH, Kassel, Germany; F. Hoffmann-La Roche, Basel, Switzerland
| | - S. R. Park
- National Institute for Neoplastic Diseases, Surquillo, Peru; Munich University of Technology, Munich, Germany; Asan Medical Center, Seoul, Republic of Korea; National Cancer Center, Goyang, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea; Aichi Cancer Center, Nagoya, Japan; University Hospital Gasthuisberg, Leuven, Belgium; TARGOS Molecular Pathology GmbH, Kassel, Germany; F. Hoffmann-La Roche, Basel, Switzerland
| | - Y. J. Bang
- National Institute for Neoplastic Diseases, Surquillo, Peru; Munich University of Technology, Munich, Germany; Asan Medical Center, Seoul, Republic of Korea; National Cancer Center, Goyang, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea; Aichi Cancer Center, Nagoya, Japan; University Hospital Gasthuisberg, Leuven, Belgium; TARGOS Molecular Pathology GmbH, Kassel, Germany; F. Hoffmann-La Roche, Basel, Switzerland
| | - A. Sawaki
- National Institute for Neoplastic Diseases, Surquillo, Peru; Munich University of Technology, Munich, Germany; Asan Medical Center, Seoul, Republic of Korea; National Cancer Center, Goyang, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea; Aichi Cancer Center, Nagoya, Japan; University Hospital Gasthuisberg, Leuven, Belgium; TARGOS Molecular Pathology GmbH, Kassel, Germany; F. Hoffmann-La Roche, Basel, Switzerland
| | - E. Van Cutsem
- National Institute for Neoplastic Diseases, Surquillo, Peru; Munich University of Technology, Munich, Germany; Asan Medical Center, Seoul, Republic of Korea; National Cancer Center, Goyang, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea; Aichi Cancer Center, Nagoya, Japan; University Hospital Gasthuisberg, Leuven, Belgium; TARGOS Molecular Pathology GmbH, Kassel, Germany; F. Hoffmann-La Roche, Basel, Switzerland
| | - O. Stoss
- National Institute for Neoplastic Diseases, Surquillo, Peru; Munich University of Technology, Munich, Germany; Asan Medical Center, Seoul, Republic of Korea; National Cancer Center, Goyang, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea; Aichi Cancer Center, Nagoya, Japan; University Hospital Gasthuisberg, Leuven, Belgium; TARGOS Molecular Pathology GmbH, Kassel, Germany; F. Hoffmann-La Roche, Basel, Switzerland
| | - B. W. Jordan
- National Institute for Neoplastic Diseases, Surquillo, Peru; Munich University of Technology, Munich, Germany; Asan Medical Center, Seoul, Republic of Korea; National Cancer Center, Goyang, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea; Aichi Cancer Center, Nagoya, Japan; University Hospital Gasthuisberg, Leuven, Belgium; TARGOS Molecular Pathology GmbH, Kassel, Germany; F. Hoffmann-La Roche, Basel, Switzerland
| | - A. Feyereislova
- National Institute for Neoplastic Diseases, Surquillo, Peru; Munich University of Technology, Munich, Germany; Asan Medical Center, Seoul, Republic of Korea; National Cancer Center, Goyang, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea; Aichi Cancer Center, Nagoya, Japan; University Hospital Gasthuisberg, Leuven, Belgium; TARGOS Molecular Pathology GmbH, Kassel, Germany; F. Hoffmann-La Roche, Basel, Switzerland
| |
Collapse
|
14
|
Maruca LJ, Ramanathan RK, Strychor S, Zamboni BA, Ramalingam S, Edwards RP, Kim JK, Bang YJ, Lee HP, Zamboni WC. Age-related effects on the pharmacodynamic (PD) relationship between STEALTH liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.2576] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2576 Background: STEALTH liposomal CKD-602 (S-CKD602), a camptothecin analogue, is eliminated by the reticuloendothelial system (RES), which consists of cells including monocytes. CKD-602 released from S-CKD602 is eliminated by the kidney. Therefore, we evaluated the PD relationship between monocyte and absolute neutrophil counts (ANC; as a control) in blood and S-CKD602 and non-liposomal CKD-602 (NL-CKD602) in patients (pts) with refractory solid tumors. We also evaluated the effect of age on these relationships. Methods: In a phase I study, S-CKD602 was administered IV x 1 q 3 wk at 0.1 to 2.5 mg/m2. In phase I and II studies, NL-CKD602 was administered IV qdx5d q 3 wk at 0.5 to 0.9 mg/m2/d and 0.5 mg/m2/d, respectively. The % decreases in ANC and monocytes at nadir were calculated. For S-CKD602, pharmacokinetic studies of encapsulated (E), released (R), and sum total (ST=E+R) CKD-602 in plasma and ST in urine were performed and measured by LC-MS/MS. Area under the plasma concentration versus time curve (AUC) was calculated. Results: For S-CKD602 in all pts (n = 27), the % decrease in ANC and monocytes were 42 ± 30 % and 58 ± 34 %, respectively (P = 0.003). For S-CKD602 in pts < 60 years old (yo) (n = 12), the % decrease in ANC and monocytes were 43 ± 31% and 58 ± 26 %, respectively (P = 0.001). For S-CKD602 in pts = 60 yo (n = 15), the % decrease in ANC and monocytes were 41 ± 31% and 45 ± 36 %, respectively (P = 0.50). For NL-CKD602 (n = 42), % decrease in ANC and monocytes were similar (P > 0.05). For S-CKD602, the relationship between % decrease in monocytes and released CKD-602 AUC in plasma in pts < 60 yo (R2 = 0.54) and = 60 yo (R2 = 0.49) was similar. For S-CKD602, the relationship between the % decrease in monocytes and the amount of CKD-602 recovered in the urine was stronger in pts < 60 yo (R2 = 0.82) compared with = 60 yo (R2 = 0.30). Conclusions: Monocytes are more sensitive to S-CKD602 compared with neutrophils and the increased sensitivity is related to the liposomal formulation and not CKD-602. These results suggest that monocytes engulf S-CKD602 which causes the release of CKD-602 from the liposome and toxicity to the monocytes, and that the effects are more prominent in pts < 60 yo. [Table: see text]
Collapse
Affiliation(s)
- L. J. Maruca
- Univ. of Pittsburgh Cancer Inst., Pittsburgh, PA; CKD Research Institute, Chonan, Democratic People’s Republic of Korea; Seoul National University Hospital, Seoul, Democratic People’s Republic of Korea
| | - R. K. Ramanathan
- Univ. of Pittsburgh Cancer Inst., Pittsburgh, PA; CKD Research Institute, Chonan, Democratic People’s Republic of Korea; Seoul National University Hospital, Seoul, Democratic People’s Republic of Korea
| | - S. Strychor
- Univ. of Pittsburgh Cancer Inst., Pittsburgh, PA; CKD Research Institute, Chonan, Democratic People’s Republic of Korea; Seoul National University Hospital, Seoul, Democratic People’s Republic of Korea
| | - B. A. Zamboni
- Univ. of Pittsburgh Cancer Inst., Pittsburgh, PA; CKD Research Institute, Chonan, Democratic People’s Republic of Korea; Seoul National University Hospital, Seoul, Democratic People’s Republic of Korea
| | - S. Ramalingam
- Univ. of Pittsburgh Cancer Inst., Pittsburgh, PA; CKD Research Institute, Chonan, Democratic People’s Republic of Korea; Seoul National University Hospital, Seoul, Democratic People’s Republic of Korea
| | - R. P. Edwards
- Univ. of Pittsburgh Cancer Inst., Pittsburgh, PA; CKD Research Institute, Chonan, Democratic People’s Republic of Korea; Seoul National University Hospital, Seoul, Democratic People’s Republic of Korea
| | - J. K. Kim
- Univ. of Pittsburgh Cancer Inst., Pittsburgh, PA; CKD Research Institute, Chonan, Democratic People’s Republic of Korea; Seoul National University Hospital, Seoul, Democratic People’s Republic of Korea
| | - Y. J. Bang
- Univ. of Pittsburgh Cancer Inst., Pittsburgh, PA; CKD Research Institute, Chonan, Democratic People’s Republic of Korea; Seoul National University Hospital, Seoul, Democratic People’s Republic of Korea
| | - H. P. Lee
- Univ. of Pittsburgh Cancer Inst., Pittsburgh, PA; CKD Research Institute, Chonan, Democratic People’s Republic of Korea; Seoul National University Hospital, Seoul, Democratic People’s Republic of Korea
| | - W. C. Zamboni
- Univ. of Pittsburgh Cancer Inst., Pittsburgh, PA; CKD Research Institute, Chonan, Democratic People’s Republic of Korea; Seoul National University Hospital, Seoul, Democratic People’s Republic of Korea
| |
Collapse
|
15
|
Abstract
The purpose of this study is to document infection and to better understand current practice relating to antibiotic use and its effect in terminal cancer patients. We retrospectively reviewed patients with terminal stage cancer who were admitted to Seoul National University Boramae Hospital for symptom control only, and who finally died between March 2003 and April 2004. A total of 141 patients were enrolled. Mean duration from admission to death was 31.2 days. A total of 104 patients (75.2%) experienced a febrile episode, and physicians considered 113 patients (80.1%) developed a clinical infection. Total 119 patients (84.4%) received antibiotics. For 90 patients (63.8%), antibiotics were used until the day of death. After using antibiotics, 48% of fevers were controlled, and 31% of organism-proven cases were resolved. Symptomatic improvement of infection was achieved in 18 patients (15.1%), but 66 patients (55.4%) showed no improvement. Improved leucocytosis was achieved by 17% and C Reactive Protein elevation by 29%. In conclusion, our study reveals a high rate of infection and a high rate of antibiotic prescription during the last month of life in cancer patients. But symptomatic improvement was not achieved in more than half of the patients. Further study should be undertaken to clarify the benefit of antibiotics in terminal stage cancer patients.
Collapse
Affiliation(s)
- D Y Oh
- Seoul National University Boramae Hospital, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Han SW, Kim TY, Lee KW, Oh DY, Lee SH, Kim DW, Chung DH, Im SA, Heo DS, Bang YJ. EGFR mutation and intron 1 CA repeat polymorphism as predictive markers of gefitinib responsiveness in non-small cell lung cancer (NSCLC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7173 Background: EGFR mutation is significantly associated with objective response and prolonged survival in NSCLC patients treated with gefitinib. However, presence of mutant nonresponses and nonmutant responses mandates investigation of other molecular markers for more effective prediction of gefitinib sensitivity in NSCLC. It is unclear whether low CA repeat number in EGFR intron 1 has such a predictive role. Methods: Advanced NSCLC patients received gefitinib 250mg/day. EGFR mutation in exons 18 - 21 were identified by direct sequencing of PCR products of DNA extracted from archival paraffin embedded tissue. Number of CA repeat in intron 1 of EGFR was determined by GeneScan with tumoral DNA. Baseline characteristics, mutational status, CA repeat number and efficacy of gefitinib were analyzed in respect to each other. Results: To date, 73 patients were evaluable for EGFR mutation, CA repeat and gefitinib responsiveness. 14 patients (19.2%) harbored EGFR mutation (7 deletion in exon 19, 4 L858R, 1 L861Q, 1 G719A, and 1 insertion in exon 20). Most common CA repeat genotype was 20/20 repeat (31 patients) followed by 16/20 repeat (15 patients). Patients were classified as having either low CA repeat (sum of both allele ≤ 37 repeats) or high CA repeat (≥ 38 repeats). 34 patients (46.6%) had low repeat, whereas 39 patients (53.4%) had high repeat. Patients with EGFR mutation showed better objective response (response rate [RR] 57.1% vs. 10.2% in wild type [WT], p < 0.001), time-to-progression (TTP) (p = 0.031, median 5.1 vs. 1.9 months in WT), and overall survival (OS) (p = 0.051, median14.5 vs. 7.4 months in WT). In the whole study population, low CA repeat was not associated with RR (p = 0.38), TTP (p = 0.15), or OS (p = 0.51). However, in the 59 patients without an EGFR mutation, patients with low CA repeat tended to have better objective response (RR 17.2% [5/29] in low repeat vs. 3.3% [1/30] in high repeat, p = 0.10) and significantly better TTP (p = 0.019, median 2.2 months in low repeat vs. 1.2 months in high repeat). Conclusions: Our results suggest that low number of CA repeats in EGFR intron 1 may have possible role in prediction of gefitinib responsiveness when analyzed together with EGFR mutational status. [Table: see text]
Collapse
Affiliation(s)
- S. W. Han
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - T. Y. Kim
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - K. W. Lee
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - D. Y. Oh
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - S. H. Lee
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - D. W. Kim
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - D. H. Chung
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - S. A. Im
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - D. S. Heo
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Y. J. Bang
- Seoul National University College of Medicine, Seoul, Republic of Korea
| |
Collapse
|
17
|
Park YH, Lee JJ, Ryu MH, Kim SY, Kim DH, Do YR, Lee KH, Oh SJ, Kim YK, Suh CW, Heo DS, Ryoo BY, Kim JK, Song HS, Lee WS, Kim HJ, Bang YJ, Yang SH, Sohn SK, Kang YK. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients. Ann Hematol 2006; 85:257-62. [PMID: 16416337 DOI: 10.1007/s00277-005-0060-6] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2005] [Accepted: 11/24/2005] [Indexed: 10/25/2022]
Abstract
The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has been shown to improve the outcome in all age groups with newly diagnosed diffuse large B-cell lymphoma (DLBCL). We conducted a retrospective analysis to evaluate the impact of this combination therapy on DLBCL outcomes in Korea. From October 2001 to June 2004, newly diagnosed DLBCL patients in nine Korean institutes were included. All of these 81 patients were treated with three or more cycles of rituximab plus CHOP (R-CHOP) combination chemotherapy (R group), and followed for a minimum of 12 months. For comparison, a historical cohort of patients was used and analyzed for "Clinicopathologic characteristics of Korean non-Hodgkin's lymphomas (NHLs) based on Revised American Lymphoma (REAL) classification" in 1999. Among the 1,098 NHL patients, the data of 214 DLBCL patients, who were treated with CHOP chemotherapy in first-line, were analyzed (C group). We compared outcomes between the C group and the R group. A total of 295 patients were evaluated (C group, 214; R group, 81). The complete response (CR) rate was higher in R group (73 vs 91%, p=0.001). The 2-year event-free survival (EFS) rate was significantly higher in R group (78 vs 85%, p=0.0194). This survival benefit was maintained in high-risk patients according to the international prognostic index (IPI) (p=0.0039), regardless of age. However, there was no significant difference in low-risk patients. The addition of rituximab to CHOP combination chemotherapy for DLBCLs showed improved outcomes, particularly in high-risk group according to the IPI. Long-term follow-up results will be needed to confirm these results.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal/administration & dosage
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Combined Chemotherapy Protocols/standards
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Cohort Studies
- Cyclophosphamide/administration & dosage
- Cyclophosphamide/standards
- Cyclophosphamide/therapeutic use
- Data Interpretation, Statistical
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Doxorubicin/administration & dosage
- Doxorubicin/standards
- Doxorubicin/therapeutic use
- Drug Administration Schedule
- Female
- Humans
- Infusions, Intravenous
- Korea
- Lymphoma, B-Cell/diagnosis
- Lymphoma, B-Cell/drug therapy
- Lymphoma, B-Cell/radiotherapy
- Lymphoma, Large B-Cell, Diffuse/diagnosis
- Lymphoma, Large B-Cell, Diffuse/drug therapy
- Lymphoma, Large B-Cell, Diffuse/radiotherapy
- Male
- Middle Aged
- Multivariate Analysis
- Neoplasm Staging
- Prednisone/administration & dosage
- Prednisone/standards
- Prednisone/therapeutic use
- Regression Analysis
- Retrospective Studies
- Rituximab
- Survival Analysis
- Treatment Outcome
- Vincristine/administration & dosage
- Vincristine/standards
- Vincristine/therapeutic use
Collapse
Affiliation(s)
- Y H Park
- Korea Cancer Center Hospital, Seoul, South Korea
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Kim JS, Kim MA, Kim DW, Im SA, Kim TY, Yang HK, Kim WH, Heo DS, Bang YJ, Kim NK. Pharmacogenomic analysis to predict relapse in curatively resected gastric cancer patients treated with adjuvant 5-fluorouracil/cisplatin (FP) chemotherapy. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J. S. Kim
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea
| | - M. A. Kim
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea
| | - D. W. Kim
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea
| | - S. A. Im
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea
| | - T. Y. Kim
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea
| | - H. K. Yang
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea
| | - W. H. Kim
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea
| | - D. S. Heo
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea
| | - Y. J. Bang
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea
| | - N. K. Kim
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea
| |
Collapse
|
19
|
Keam B, Keam B, Han SW, Ham HS, Kim DW, Im SA, Kim TY, Yoon SS, Heo DS, Bang YJ, Kim NK. Pharmacogenomic prediction of response in advanced gastric cancer (AGC) patients receiving 5-Fluorouracil (FU)/leucovorin (LV)/oxaliplatin (OX) as first-line palliative chemotherapy. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- B. Keam
- Seoul National Univ Hosp, Seoul, Republic of Korea; Cancer Research Institute, Seoul, Republic of Korea
| | - B. Keam
- Seoul National Univ Hosp, Seoul, Republic of Korea; Cancer Research Institute, Seoul, Republic of Korea
| | - S. W. Han
- Seoul National Univ Hosp, Seoul, Republic of Korea; Cancer Research Institute, Seoul, Republic of Korea
| | - H. S. Ham
- Seoul National Univ Hosp, Seoul, Republic of Korea; Cancer Research Institute, Seoul, Republic of Korea
| | - D. W. Kim
- Seoul National Univ Hosp, Seoul, Republic of Korea; Cancer Research Institute, Seoul, Republic of Korea
| | - S. A. Im
- Seoul National Univ Hosp, Seoul, Republic of Korea; Cancer Research Institute, Seoul, Republic of Korea
| | - T. Y. Kim
- Seoul National Univ Hosp, Seoul, Republic of Korea; Cancer Research Institute, Seoul, Republic of Korea
| | - S. S. Yoon
- Seoul National Univ Hosp, Seoul, Republic of Korea; Cancer Research Institute, Seoul, Republic of Korea
| | - D. S. Heo
- Seoul National Univ Hosp, Seoul, Republic of Korea; Cancer Research Institute, Seoul, Republic of Korea
| | - Y. J. Bang
- Seoul National Univ Hosp, Seoul, Republic of Korea; Cancer Research Institute, Seoul, Republic of Korea
| | - N. K. Kim
- Seoul National Univ Hosp, Seoul, Republic of Korea; Cancer Research Institute, Seoul, Republic of Korea
| |
Collapse
|
20
|
Lee KH, Han SW, Jeong S, Kim DW, Chung DH, Im SA, Kim TY, Heo DS, Bang YJ, Kim NK. EGFR mutation and response to chemotherapy in non-small-cell lung cancer (NSCLC) patients. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7084] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- K. H. Lee
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; ISU ABXIS, Seoul, Republic of Korea; Cancer Research Institute, Seoul National Univ, Seoul, Republic of Korea
| | - S. W. Han
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; ISU ABXIS, Seoul, Republic of Korea; Cancer Research Institute, Seoul National Univ, Seoul, Republic of Korea
| | - S. Jeong
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; ISU ABXIS, Seoul, Republic of Korea; Cancer Research Institute, Seoul National Univ, Seoul, Republic of Korea
| | - D. W. Kim
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; ISU ABXIS, Seoul, Republic of Korea; Cancer Research Institute, Seoul National Univ, Seoul, Republic of Korea
| | - D. H. Chung
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; ISU ABXIS, Seoul, Republic of Korea; Cancer Research Institute, Seoul National Univ, Seoul, Republic of Korea
| | - S. A. Im
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; ISU ABXIS, Seoul, Republic of Korea; Cancer Research Institute, Seoul National Univ, Seoul, Republic of Korea
| | - T. Y. Kim
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; ISU ABXIS, Seoul, Republic of Korea; Cancer Research Institute, Seoul National Univ, Seoul, Republic of Korea
| | - D. S. Heo
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; ISU ABXIS, Seoul, Republic of Korea; Cancer Research Institute, Seoul National Univ, Seoul, Republic of Korea
| | - Y. J. Bang
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; ISU ABXIS, Seoul, Republic of Korea; Cancer Research Institute, Seoul National Univ, Seoul, Republic of Korea
| | - N. K. Kim
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; ISU ABXIS, Seoul, Republic of Korea; Cancer Research Institute, Seoul National Univ, Seoul, Republic of Korea
| |
Collapse
|
21
|
Kim TM, Kim JS, Im SA, Kim TY, Yang HK, Kim WH, Heo DS, Bang YJ, Lee KU, Kim NK. Adjuvant 5-FU/cisplatin (FP) chemotherapy in curatively resected stage IIIA-IV M0 gastric cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- T. M. Kim
- Seoul National Univ Hosp, Seoul, Republic of Korea
| | - J. S. Kim
- Seoul National Univ Hosp, Seoul, Republic of Korea
| | - S.-A. Im
- Seoul National Univ Hosp, Seoul, Republic of Korea
| | - T. Y. Kim
- Seoul National Univ Hosp, Seoul, Republic of Korea
| | - H. K. Yang
- Seoul National Univ Hosp, Seoul, Republic of Korea
| | - W. H. Kim
- Seoul National Univ Hosp, Seoul, Republic of Korea
| | - D. S. Heo
- Seoul National Univ Hosp, Seoul, Republic of Korea
| | - Y. J. Bang
- Seoul National Univ Hosp, Seoul, Republic of Korea
| | - K. U. Lee
- Seoul National Univ Hosp, Seoul, Republic of Korea
| | - N. K. Kim
- Seoul National Univ Hosp, Seoul, Republic of Korea
| |
Collapse
|
22
|
Han SW, Jeong S, Choi IS, Kim DW, Chung DH, Im SA, Kim TY, Heo DS, Bang YJ, Kim NK. EGFR and K-ras mutations as determinants of gefitinib sensitivity in non-small-cell lung cancer (NSCLC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7078] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. W. Han
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; ISU ABXIS, Inc., Seoul, Republic of Korea; Seoul Municipal Boramae Hosp, Seoul, Republic of Korea; Cancer Research Institute, Seoul National Univ, Seoul, Republic of Korea
| | - S. Jeong
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; ISU ABXIS, Inc., Seoul, Republic of Korea; Seoul Municipal Boramae Hosp, Seoul, Republic of Korea; Cancer Research Institute, Seoul National Univ, Seoul, Republic of Korea
| | - I. S. Choi
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; ISU ABXIS, Inc., Seoul, Republic of Korea; Seoul Municipal Boramae Hosp, Seoul, Republic of Korea; Cancer Research Institute, Seoul National Univ, Seoul, Republic of Korea
| | - D. W. Kim
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; ISU ABXIS, Inc., Seoul, Republic of Korea; Seoul Municipal Boramae Hosp, Seoul, Republic of Korea; Cancer Research Institute, Seoul National Univ, Seoul, Republic of Korea
| | - D. H. Chung
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; ISU ABXIS, Inc., Seoul, Republic of Korea; Seoul Municipal Boramae Hosp, Seoul, Republic of Korea; Cancer Research Institute, Seoul National Univ, Seoul, Republic of Korea
| | - S.-A. Im
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; ISU ABXIS, Inc., Seoul, Republic of Korea; Seoul Municipal Boramae Hosp, Seoul, Republic of Korea; Cancer Research Institute, Seoul National Univ, Seoul, Republic of Korea
| | - T. Y. Kim
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; ISU ABXIS, Inc., Seoul, Republic of Korea; Seoul Municipal Boramae Hosp, Seoul, Republic of Korea; Cancer Research Institute, Seoul National Univ, Seoul, Republic of Korea
| | - D. S. Heo
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; ISU ABXIS, Inc., Seoul, Republic of Korea; Seoul Municipal Boramae Hosp, Seoul, Republic of Korea; Cancer Research Institute, Seoul National Univ, Seoul, Republic of Korea
| | - Y. J. Bang
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; ISU ABXIS, Inc., Seoul, Republic of Korea; Seoul Municipal Boramae Hosp, Seoul, Republic of Korea; Cancer Research Institute, Seoul National Univ, Seoul, Republic of Korea
| | - N. K. Kim
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; ISU ABXIS, Inc., Seoul, Republic of Korea; Seoul Municipal Boramae Hosp, Seoul, Republic of Korea; Cancer Research Institute, Seoul National Univ, Seoul, Republic of Korea
| |
Collapse
|
23
|
Hong YS, Park YH, Kim DW, Im SA, Kim TY, Yoon SS, Heo DS, Bang YJ, Park S, Kim NK. Clinical presentation pattern is more closely associated with treatment outcome than histologic subtypes in Castleman’s disease. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.6635] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Y. S. Hong
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; Korean Ctr Ctr Hosp, Seoul, Republic of Korea; Cancer Research Institute, Seoul National Univ, Seoul, Republic of Korea
| | - Y. H. Park
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; Korean Ctr Ctr Hosp, Seoul, Republic of Korea; Cancer Research Institute, Seoul National Univ, Seoul, Republic of Korea
| | - D. W. Kim
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; Korean Ctr Ctr Hosp, Seoul, Republic of Korea; Cancer Research Institute, Seoul National Univ, Seoul, Republic of Korea
| | - S. A. Im
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; Korean Ctr Ctr Hosp, Seoul, Republic of Korea; Cancer Research Institute, Seoul National Univ, Seoul, Republic of Korea
| | - T. Y. Kim
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; Korean Ctr Ctr Hosp, Seoul, Republic of Korea; Cancer Research Institute, Seoul National Univ, Seoul, Republic of Korea
| | - S. S. Yoon
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; Korean Ctr Ctr Hosp, Seoul, Republic of Korea; Cancer Research Institute, Seoul National Univ, Seoul, Republic of Korea
| | - D. S. Heo
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; Korean Ctr Ctr Hosp, Seoul, Republic of Korea; Cancer Research Institute, Seoul National Univ, Seoul, Republic of Korea
| | - Y. J. Bang
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; Korean Ctr Ctr Hosp, Seoul, Republic of Korea; Cancer Research Institute, Seoul National Univ, Seoul, Republic of Korea
| | - S. Park
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; Korean Ctr Ctr Hosp, Seoul, Republic of Korea; Cancer Research Institute, Seoul National Univ, Seoul, Republic of Korea
| | - N. K. Kim
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; Korean Ctr Ctr Hosp, Seoul, Republic of Korea; Cancer Research Institute, Seoul National Univ, Seoul, Republic of Korea
| |
Collapse
|
24
|
Lee KW, Oh DY, Kim JH, Kim DW, Im SA, Kim TY, Yoon SS, Heo DS, Bang YJ, Kim NK. Phase II study of low-dose paclitaxel and cisplatin as second-line therapy in 5-fluorouracil and platinum pretreated gastric cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- K. W. Lee
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; Cancer Research Institute, Seoul, Republic of Korea
| | - D. Y. Oh
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; Cancer Research Institute, Seoul, Republic of Korea
| | - J. H. Kim
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; Cancer Research Institute, Seoul, Republic of Korea
| | - D. W. Kim
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; Cancer Research Institute, Seoul, Republic of Korea
| | - S. A. Im
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; Cancer Research Institute, Seoul, Republic of Korea
| | - T. Y. Kim
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; Cancer Research Institute, Seoul, Republic of Korea
| | - S. S. Yoon
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; Cancer Research Institute, Seoul, Republic of Korea
| | - D. S. Heo
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; Cancer Research Institute, Seoul, Republic of Korea
| | - Y. J. Bang
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; Cancer Research Institute, Seoul, Republic of Korea
| | - N. K. Kim
- Seoul National Univ Coll of Medicine, Seoul, Republic of Korea; Cancer Research Institute, Seoul, Republic of Korea
| |
Collapse
|
25
|
Kim DY, Lee KW, Yun T, Kim JH, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ, Kim NK. Efficacy of platinum-based chemotherapy after cranial irradiation in patients with brain metastasis from non-small cell lung cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.1575] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- D. Y. Kim
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - K. W. Lee
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - T. Yun
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - J. H. Kim
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - D. W. Kim
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - S. A. Im
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - T. Y. Kim
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - D. S. Heo
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Y. J. Bang
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - N. K. Kim
- Seoul National University College of Medicine, Seoul, Republic of Korea
| |
Collapse
|
26
|
Sun JM, Han W, Kim DW, Kim TY, Park IAE, Noh DY, Heo DS, Bang YJ, Choe KJ, Kim NK. Clinical relevance of HER-2 expression in node-negative breast cancer patients. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.598] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J. M. Sun
- Seoul National University Hospital, Seoul, Republic of Korea
| | - W. Han
- Seoul National University Hospital, Seoul, Republic of Korea
| | - D. W. Kim
- Seoul National University Hospital, Seoul, Republic of Korea
| | - T. Y. Kim
- Seoul National University Hospital, Seoul, Republic of Korea
| | - I. A. E. Park
- Seoul National University Hospital, Seoul, Republic of Korea
| | - D. Y. Noh
- Seoul National University Hospital, Seoul, Republic of Korea
| | - D. S. Heo
- Seoul National University Hospital, Seoul, Republic of Korea
| | - Y. J. Bang
- Seoul National University Hospital, Seoul, Republic of Korea
| | - K. J. Choe
- Seoul National University Hospital, Seoul, Republic of Korea
| | - N. K. Kim
- Seoul National University Hospital, Seoul, Republic of Korea
| |
Collapse
|
27
|
Lee KW, Kim DW, Im SA, Kim TY, Yoon SS, Heo DS, Bang YJ, Park S, Kim BK, Kim NK. Efficacy of ifosfamide, methotrexate, etoposide and prednisone (IMEP) chemotherapy in extranodal NK/T-cell lymphoma, nasal type. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.6685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- K. W. Lee
- Seoul National University Hospital, Seoul, Republic of Korea
| | - D. W. Kim
- Seoul National University Hospital, Seoul, Republic of Korea
| | - S. A. Im
- Seoul National University Hospital, Seoul, Republic of Korea
| | - T. Y. Kim
- Seoul National University Hospital, Seoul, Republic of Korea
| | - S. S. Yoon
- Seoul National University Hospital, Seoul, Republic of Korea
| | - D. S. Heo
- Seoul National University Hospital, Seoul, Republic of Korea
| | - Y. J. Bang
- Seoul National University Hospital, Seoul, Republic of Korea
| | - S. Park
- Seoul National University Hospital, Seoul, Republic of Korea
| | - B. K. Kim
- Seoul National University Hospital, Seoul, Republic of Korea
| | - N. K. Kim
- Seoul National University Hospital, Seoul, Republic of Korea
| |
Collapse
|
28
|
Kim TY, Kim SI, Park SR, Paek JY, Choi IS, Kim DW, Kim TY, Heo DS, Bang YJ, Kim NK. Outcomes of crossover treatments with paclitaxel- or gemcitabine-based combination chemotherapy for non-small cell lung cancer (NSCLC). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- T. Y. Kim
- Seoul National University Hospital, Seoul, Republic of Korea
| | - S. I. Kim
- Seoul National University Hospital, Seoul, Republic of Korea
| | - S. R. Park
- Seoul National University Hospital, Seoul, Republic of Korea
| | - J. Y. Paek
- Seoul National University Hospital, Seoul, Republic of Korea
| | - I. S. Choi
- Seoul National University Hospital, Seoul, Republic of Korea
| | - D. W. Kim
- Seoul National University Hospital, Seoul, Republic of Korea
| | - T. Y. Kim
- Seoul National University Hospital, Seoul, Republic of Korea
| | - D. S. Heo
- Seoul National University Hospital, Seoul, Republic of Korea
| | - Y. J. Bang
- Seoul National University Hospital, Seoul, Republic of Korea
| | - N. K. Kim
- Seoul National University Hospital, Seoul, Republic of Korea
| |
Collapse
|
29
|
Han SW, Hwang PG, Chung DH, Kim JH, Kim DW, Kim TY, Heo DS, Bang YJ, Kim NK. Gefitinib monotherapy in previously treated advanced non-small cell lung cancer (NSCLC): An immunohistochemical (IHC) analysis of EGFR and its downstream molecules. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. W. Han
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - P. G. Hwang
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - D. H. Chung
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - J. H. Kim
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - D. W. Kim
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - T. Y. Kim
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - D. S. Heo
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Y. J. Bang
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - N. K. Kim
- Seoul National University College of Medicine, Seoul, Republic of Korea
| |
Collapse
|
30
|
Choi IS, Oh DY, Kim DW, Kim YT, Kim TY, Yoo CK, Kim YW, Heo DS, Bang YJ, Kim NK. Phase II study of neoadjuvant chemotherapy with paclitaxel and cisplatin in Stage IIIA N2 non-small cell lung cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7305] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- I. S. Choi
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - D. Y. Oh
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - D. W. Kim
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Y. T. Kim
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - T. Y. Kim
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - C. K. Yoo
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Y. W. Kim
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - D. S. Heo
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Y. J. Bang
- Seoul National University College of Medicine, Seoul, Republic of Korea
| | - N. K. Kim
- Seoul National University College of Medicine, Seoul, Republic of Korea
| |
Collapse
|
31
|
Kang YK, Park YH, Ryoo BY, Bang YJ, Cho KS, Shin DB, Kim HC, Lee KH, Park YS, Lee KS, Heo DS, Kim SY, Cho EK, Lim HY, Kim WK, Lee JA, Kim TY, Lee JC, Yoon HJ, Kim NK. Ramosetron for the prevention of cisplatin-induced acute emesis: a prospective randomized comparison with granisetron. J Int Med Res 2002; 30:220-9. [PMID: 12166338 DOI: 10.1177/147323000203000302] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Control of nausea and vomiting is very important in determining patient compliance with cisplatin chemotherapy. A multicentre, randomized, single-blind study was conducted to compare the tolerability and efficacy of ramosetron with those of granisetron over 24 h following cisplatin administration to cancer patients. In eight study centres, a total of 194 adult patients were randomly assigned to receive either intravenous ramosetron 0.3 mg or intravenous granisetron 3.0 mg. The anti-emetic effect of ramosetron determined from the no-vomiting rate lasted longer, but there was no significant difference in the number of acute vomiting episodes or the severity of nausea between the two groups. In the tolerability evaluation, there were no statistically significant differences between the two groups, except for a higher incidence of dull headache in the granisetron group. Ramosetron and granisetron appear to have equivalent efficacy and tolerability profiles, but the effects of ramosetron on the prevention of acute vomiting in patients undergoing cisplatin chemotherapy were longer lasting.
Collapse
Affiliation(s)
- Y K Kang
- Department of Internal Medicine, Korea Cancer Centre Hospital, Seoul, Korea.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Joh YH, Kim TY, Na II, Oh DY, Kim BS, Kim JH, Kim DY, Lee SH, Yoo CG, Lee CT, Kim YW, Heo DS, Bang YJ, Han SK, Shim YS, Kim NK. Phase II Trial of Vinorelbine and Cisplatin Chemotherapy in Advanced Non-Small Cell Lung Cancer. Cancer Res Treat 2001; 33:373-6. [PMID: 26680810 DOI: 10.4143/crt.2001.33.5.373] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
PURPOSE Platinum-based chemotherapy has conferred a modest but significant survival benefit and the introduction of newer drugs has led to achieve higher response rate in patients with advanced non-small cell lung cancer (NSCLC). We performed a phase II trial in order to evaluate the efficacy and toxicity of combination chemotherapy with vinorelbine (Navelbine) and cisplatin in advanced NSCLC. MATERIALS AND METHODS Patients with previously untreated, unresectable stage IIIB or IV NSCLC with measurable lesion (s) were eligible for entry into the study. NP chemotherapy consisted of intravenous vinorelbine 25 mg/m2, on day 1 and 8, and intravenous cisplatin 80 mg/m2 on day 1; this cycle was repeated every three weeks. RESULTS A total of 33 patients were enrolled in the study between July 1999 and Feb 2000. Of the 30 patients deemed eligible for analysis, thirteen patients achieved a partial response and thirteen showed a stable disease. The overall response rate was 43.3%. The median duration of response was 5.7 months (95% CI: 2.8~8.5 months). The median time to progression was 7.6 months (95% CI: 5.5~9.7 months) and the overall median survival time was 15.1 months (95% CI: 9.8~20.4 months) in the intent-to-treat analysis. Chemotherapy-related grade 3 or 4 toxicities were anemia in 1.5%, leukopenia in 4.5%, nausea/vomiting in 2.3%, alopecia in 13.3%, and neurotoxicity in 3.3%. CONCLUSION The combination of vinorelbine and cisplatin chemotherapy seems to be active and fairly tolerable in patients with advanced NSCLC.
Collapse
|
33
|
Kim HK, Park IA, Heo DS, Noh DY, Choe KJ, Bang YJ, Kim NK. Cyclin E overexpression as an independent risk factor of visceral relapse in breast cancer. Eur J Surg Oncol 2001; 27:464-71. [PMID: 11504517 DOI: 10.1053/ejso.2001.1137] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
AIM Prognostic value of the cyclin E overexpression in breast cancer has not been clearly established, especially in relation to the pattern of recurrence. We investigated the implication of cyclin E overexpression for the pattern of recurrence in Korean breast cancer patients. METHODS Using immunohistochemical methods, we retrospectively examined the cyclin E expression level in breast cancer specimens from 128 women who underwent curative breast surgery, and correlated the levels of expression with the pattern of relapse in patients. RESULTS Cox model-based multivariate analysis indicated that distant relapse could be predicted by the number of positive axillary lymph nodes, high cyclin E expression, and the younger age (<35 years) of the patient. We tested further the association of cyclin E overexpression with the specific types of recurrence; multivariate analyses indicated that adjusted relative risks of bone and visceral relapse as the first events among high cyclin E group were 2.46 (95% confidence interval (CI), 0.86-7.02) (P=0.092), and 3.98 (95% CI, 1.23-12.94) (P=0.022), respectively. On the other hand, cyclin E overexpression was not associated with the risk of locoregional relapse. CONCLUSION Our data suggest that cyclin E overexpression in primary breast carcinoma tissue could independently predict the risk of distant relapse, especially of visceral relapse, as the first failure after curative breast surgery.
Collapse
Affiliation(s)
- H K Kim
- Department of Internal Medicine, Seoul National University College of Medicine, 28, Yongon-dong, Chongno-gu, Seoul, 110-744, Korea
| | | | | | | | | | | | | |
Collapse
|
34
|
Abstract
OBJECTIVE The aim of this study was to determine prognostic factors of metachronous Krukenberg's tumors of gastric origin, thereby helping to establish a therapeutic plan for this rare entity. METHODS Thirty-four female patients who underwent curative resection of gastric carcinoma from 1987 through 1996 and subsequently developed Krukenberg's tumors were identified. The covariates used for survival analysis were patient age at the time of ovarian relapse (categorized as <50 years or >/=50 years), size of Krukenberg's tumor (categorized as </=5, 5-10, or >10 cm), initial AJCC stage of gastric carcinoma, relapse-free interval (categorized as <1, 1-2, or >/=2 years), extent of recurrent disease, and the presence of gross residual disease after treatment for Krukenberg's tumors. The influence of all covariates on the survival period was assessed using the Cox proportional hazards model. RESULTS At a median follow-up of 32.3 months (range, 2.2-83.1), the median survival period of 34 study patients was estimated to be 7.7 months (95% confidence interval (CI), 5.8-9.6) after the diagnosis of metachronous Krukenberg's tumor. Cox-model-based survival analysis demonstrated that the absence of residual disease after treatment and limited disease extent were favorable prognostic factors. The median survival period of patients without gross residual disease was longer (10.9 months (95% CI, 4.6-17.1)) than that of patients with gross residual disease (7.5 months (95% CI, 6.6-8.3)) [P = 0.036]. Median survival periods according to the extent of metastasis were 10.9 months (95% CI, 0-23.0) for patients with disease confined to the ovaries, 13.1 months (95% CI, 5.9-20.3) for patients with disease confined to the pelvis, 7.5 months (95% CI, 6.8-8.1) for patients with intraabdominal disease, and 3.6 months (95% CI, 3.4-3.7) for patients with disease spread outside the abdomen and pelvis [P = 0.003]. In contrast, patient age, size of ovarian tumor, initial stage of gastric adenocarcinoma, and relapse-free interval were not prognostic indicators for survival after the development of ovarian metastases. CONCLUSION The absence of residual disease after treatment and limited disease extent were favorable prognostic factors of metachronous Krukenberg's tumors of stomach origin. Our data suggest that resection might have a role in the management of Krukenberg's tumors of stomach origin if it could render patients free of gross residual disease.
Collapse
Affiliation(s)
- H K Kim
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, 110-744, Korea
| | | | | | | |
Collapse
|
35
|
Song SH, Jong HS, Choi HH, Inoue H, Tanabe T, Kim NK, Bang YJ. Transcriptional silencing of Cyclooxygenase-2 by hyper-methylation of the 5' CpG island in human gastric carcinoma cells. Cancer Res 2001; 61:4628-35. [PMID: 11389100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
It has been well established that overexpression of Cyclooxygenase-2 (Cox-2) in epithelial cells inhibits apoptosis and increases the invasiveness of malignant cells, favoring tumorigenesis and metastasis. However, the molecular mechanism that regulates Cox-2 expression has not been well defined in gastric carcinoma. In this study, we examined whether the Cox-2 expression could be regulated by hyper-methylation of the Cox-2 CpG island (spanning from -590 to +186 with respect to the transcription initiation site) in human gastric carcinoma cell lines. By Southern analysis, we found that three gastric cells (SNU-601, -620, and -719) without Cox-2 expression demonstrated hyper-methylation at the Cox-2 CpG island. A detailed methylation pattern using bisulfite sequencing analysis revealed that all of the CpG sites were completely methylated in SNU-601. Treatment with demethylating agents effectively reactivated the expression of Cox-2 and restored IL-1beta sensitivity in the previously resistant SNU-601. By transient transfection experiments, we demonstrate that constitutively active Cox-2 promoter activities were exhibited even without an exogenous stimulation in SNU-601. Furthermore, when the motif of the nuclear factor for interleukin-6 expression site, the cyclic AMP response element, or both was subjected to point mutation, the constitutive luciferase activity was markedly reduced. In addition, Cox-2 promoter activity was completely blocked by in vitro methylation of all of the CpG sites in the Cox-2 promoter region with SssI (CpG) methylase in SNU-601. Taken together, these results indicate that transcriptional repression of Cox-2 is caused by hyper-methylation of the Cox-2 CpG island in gastric carcinoma cell lines.
Collapse
Affiliation(s)
- S H Song
- Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-799, Korea
| | | | | | | | | | | | | |
Collapse
|
36
|
Lee WS, Lee KS, Kim KH, Ryoo BY, Kim WS, Kang WK, Kang YK, Heo DS, Bang YJ, Kim NK. A Phase II Trial of UFT-E and Oral Leucovorin in Advanced Colorectal Cancer. Cancer Res Treat 2001; 33:225-8. [PMID: 26680789 DOI: 10.4143/crt.2001.33.3.225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
PURPOSE To determine the efficacy and toxicity of UFT-E plus oral calcium leucovorin in the treatment of patients with advanced colorectal cancer. MATERIALS AND METHODS Forty-three patients with advanced, bidimensionally measurable colorectal adenocarcinoma were enrolled in the trial. No patients had received prior palliative chemotherapy. The patients that had received previous adjuvant chemotherapy were enrolled when more than 6 months had elapsed after the completion of adjuvant therapy. Patients were treated with 300 mg/m2/day of UFT-E (tegafur-based) plus 90 mg/day of leucovorin administered orally in three divided daily doses, every 8 hours for 28 days followed by a 7-day rest period. Response was evaluated after two or three courses of therapy. RESULTS Thirty-six of forty-three patients were evaluable for response; seven dropped out due to infection, toxicity and patients' refusal. Ten patients had partial responses and one patient complete response (response rate, 31%; 95% confidence interval, 16~46%). The median response duration for the UFT-E plus leucovorin regimen was 28 weeks. Grade III toxicity was seen in one case, with diarrhea. CONCLUSION This oral regimen proved effective and well tolerated. This schema also avoided inconveniences, such as hospitalization and the use of infusion pumps, which are associated with 5-FU infusion regimens. The regimen used showed minimal toxicity, especially in the upper digestive tract, with good patient compliance.
Collapse
|
37
|
Oh JE, Bang YJ, Ahn C, Oh MD, Whang DY, Kim KW, Han JS, Kim S, Lee JS, Kim SJ, Kim SH, Lee HS. Polyomavirus interstitial nephritis in a patient with EBV-negative B-cell posttransplantation lymphoproliferative disorder. Transplant Proc 2001; 33:2583-7. [PMID: 11406254 DOI: 10.1016/s0041-1345(01)02104-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- J E Oh
- Division of Nephrology, Seoul National University Hospital, Seoul, South Korea
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Kim NK, Kim TY, Shin SG, Park YI, Lee JA, Cho YB, Kim KH, Kim DK, Heo DS, Bang YJ. A Phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II) in patients with advanced malignancies. Cancer 2001; 91:1549-56. [PMID: 11301404 DOI: 10.1002/1097-0142(20010415)91:8<1549::aid-cncr1164>3.0.co;2-2] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND A Phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II) (SKI 2053R), a new platinum derivative, was performed to determine the maximum tolerated dose (MTD), the dose limiting toxicities (DLTs), and the pharmacokinetic profile of SKI 2053R in patients with advanced, refractory malignancies. METHODS Twenty-one patients were entered into the study. SKI 2053R was administered with an intravenous infusion over 1 hour every 4 weeks. The SKI 2053R dose was escalated from 40 mg/m(2) up to 480 mg/m(2) using a modified Fibonacci scheme. Pharmacokinetic analysis was done in all patients to determine the total and ultrafiltrable platinum concentrations in both the plasma and the urine. RESULTS All patients were evaluable for toxicity and response. There was no significant toxicity with dosages up to 360 mg/m(2). At 480 mg/m(2), two of three patients developed Grade 4 hepatotoxicity, Grade 3 leukopenia and thrombocytopenia, and Grade 2 azotemia and proteinuria. Other toxicity included nausea and emesis, but it was controlled with antiemetics. SKI 2053R did not cause significant neurotoxicity or mucositis. There were 4 patients with stable disease among the 21 patients. Plasma decay of the total and free platinum concentrations was best fitted by using a two-compartment, open model. The terminal plasma half-life of the total platinum after SKI 2053R administration ranged from 63.4 hours to 114.1 hours in dosages ranging from 40 mg/m(2) to 480 mg/m(2) without significant dose dependency. However, the terminal plasma half-life of the free platinum concentration showed a significant dose dependent, incremental pattern. The renal excretion of SKI 2053R measured as platinum ranged from 49% to 75% of the administered dose. CONCLUSIONS The MTD of SKI 2053R was 480 mg/m(2). The major DLTs were hepatotoxicity, nephrotoxicity, and myelosuppression. The recommended starting dose for a subsequent Phase II study is 360 mg/m(2) once every 4 weeks.
Collapse
Affiliation(s)
- N K Kim
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
| | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Kang WK, Park C, Yoon HL, Kim WS, Yoon SS, Lee MH, Park K, Kim K, Jeong HS, Kim JA, Nam SJ, Yang JH, Son YI, Baek CH, Han J, Ree HJ, Lee ES, Kim SH, Kim DW, Ahn YC, Huh SJ, Choe YH, Lee JH, Park MH, Kong GS, Park EY, Kang YK, Bang YJ, Paik NS, Lee SN, Kim SH, Kim S, Robbins PD, Tahara H, Lotze MT, Park CH. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum Gene Ther 2001; 12:671-84. [PMID: 11426466 DOI: 10.1089/104303401300057388] [Citation(s) in RCA: 99] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
Abstract
A phase I dose-escalation clinical trial of peritumoral injections of interleukin 12 (IL-12)-transduced autologous fibroblasts was performed in patients with disseminated cancer for whom effective treatment does not exist. The goals of this study were to assess the safety and toxicities as well as the efficacy, and ancillarily the immunomodulatory effects, of peritumoral IL-12 gene transfer. Primary dermal fibroblasts cultured from the patients were transduced with retroviral vector carrying human IL-12 genes (p35 and p40) as well as the neomycin phosphotransferase gene (TFG-hIL-12-Neo). Patients received four injections at intervals of 7 days. Nine patients were enrolled in this dose-escalation study, with secreted IL-12 doses ranging from 300 ng/24 hr for the first three patients to 1000, 3000, and 5000 ng/24 hr for two patients in each subsequent dosage level. Although a definite statement cannot be made, there appears to be perturbation of systemic immunity. Also, the locoregional effects mediated by tumor necrosis factor alpha (TNF-alpha) and CD8+ T cells were observed with tumor regression. Treatment-related adverse events were limited to mild to moderate pain at the injection site; clinically significant toxicities were not encountered. Transient but clear reductions of tumor sizes were observed at the injected sites in four of nine cases, and at noninjected distant sites in one melanoma patient. Hemorrhagic necrosis of tumors was observed in two melanoma patients. These data indicate that gene therapy by peritumoral injection of IL-12-producing autologous fibroblasts is feasible, and promising in patients with advanced cancer.
Collapse
Affiliation(s)
- W K Kang
- Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Kim SG, Kim SN, Jong HS, Kim NK, Hong SH, Kim SJ, Bang YJ. Caspase-mediated Cdk2 activation is a critical step to execute transforming growth factor-beta1-induced apoptosis in human gastric cancer cells. Oncogene 2001; 20:1254-65. [PMID: 11313870 DOI: 10.1038/sj.onc.1204203] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2000] [Revised: 12/14/2000] [Accepted: 12/19/2000] [Indexed: 01/07/2023]
Abstract
Although TGF-beta1, a growth inhibitor, is known to also induce apoptosis, the molecular mechanism of this apoptosis is largely undefined. Here, we identify the mechanism of TGF-beta1-induced apoptosis in SNU-16 human gastric cancer cells. Cell cycle and TUNEL analysis showed that, upon TGF-beta1 treatment, cells were initially arrested at the G1 phase and then driven into apoptosis. Of note, caspase-3 was activated in accordance with TGF-beta1-induced G1 arrest. Activated caspase-3 is targeted to cleave p21(cip1), p27(kip1), and Rb, which play important roles in TGF-beta-induced G1 arrest, into inactive fragments. Subsequently, Cdk2 was aberrantly activated due to the cleavage of p21 and p27. We found that the inhibition of Cdk2 activity efficiently blocks TGF-beta1-induced apoptosis, whereas it did not prevent caspase-3 activation or the subsequent cleavage of target proteins. In contrast, the suppression of caspase-3 activity inhibited the cleavage of target proteins, the activation of Cdk2, and the induction of apoptosis. Taken together, our results suggest that activation of caspase-3 by TGF-beta1 may initiate the conversion from G1 cell cycle arrest to apoptosis via the cleavage of p21, p27 and Rb, which in turn causes Cdk2 activation and, most significantly, Cdk2 activation as a downstream effector of caspase is a critical step for the execution of TGF-beta1-induced apoptosis.
Collapse
Affiliation(s)
- S G Kim
- Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-744, Korea
| | | | | | | | | | | | | |
Collapse
|
41
|
Affiliation(s)
- J H Lee
- CKD Research Institute, CKD Pharmaceutical Corporation, Seoul 152-600, Korea
| | | | | | | | | | | | | |
Collapse
|
42
|
Sohn HW, Shin YK, Lee IS, Bae YM, Suh YH, Kim MK, Kim TJ, Jung KC, Park WS, Park CS, Chung DH, Ahn K, Kim IS, Ko YH, Bang YJ, Kim CW, Park SH. CD99 regulates the transport of MHC class I molecules from the Golgi complex to the cell surface. J Immunol 2001; 166:787-94. [PMID: 11145651 DOI: 10.4049/jimmunol.166.2.787] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The down-regulation of surface expression of MHC class I molecules has recently been reported in the CD99-deficient lymphoblastoid B cell line displaying the characteristics of Hodgkin's and Reed-Sternberg phenotype. Here, we demonstrate that the reduction of MHC class I molecules on the cell surface is primarily due to a defect in the transport from the Golgi complex to the plasma membrane. Loss of CD99 did not affect the steady-state expression levels of mRNA and protein of MHC class I molecules. In addition, the assembly of MHC class I molecules and the transport from the endoplasmic reticulum to the cis-Golgi occurred normally in the CD99-deficient cells, and no difference was detected between the CD99-deficient and the control cells in the pattern and degree of endocytosis. Instead, the CD99-deficient cells displayed the delayed transport of newly synthesized MHC class I molecules to the plasma membrane, thus causing accumulation of the molecules within the cells. The accumulated MHC class I molecules in the CD99-deficient cells were colocalized with alpha-mannosidase II and gamma-adaptin in the Golgi compartment. These results suggest that CD99 may be associated with the post-Golgi trafficking machinery by regulating the transport to the plasma membrane rather than the endocytosis of surface MHC class I molecules, providing a novel mechanism of MHC class I down-regulation for immune escape.
Collapse
Affiliation(s)
- H W Sohn
- Department of. Pathology and Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Bang SM, Heo DS, Lee KH, Byun JH, Chang HM, Noh DY, Choe KJ, Bang YJ, Kim SR, Kim NK. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma. Cancer 2000; 89:2521-6. [PMID: 11135211 DOI: 10.1002/1097-0142(20001215)89:12<2521::aid-cncr2>3.0.co;2-f] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
BACKGROUND This randomized controlled trial was to determine whether a combination chemotherapy regimen that contains anthracycline (doxorubicin and cyclophosphamide [AC]) is superior to the conventional cyclophosphamide, methotrexate, and 5-fluorouracil [CMF] combination in premenopausal women with axillary lymph node positive Stage II breast carcinoma. METHODS Premenopausal women with lymph node positive breast carcinoma were stratified according to age (younger than 35 or 35 years or older) and the number of positive axillary lymph nodes (1-3, 4-9, or >/= 10) and then randomly assigned to receive either doxorubicin 40 mg/m(2) and cyclophosphamide 600 mg/m(2) intravenously (i.v.) every 3 weeks or cyclophosphamide 100 mg/m(2) orally on Days 1 through 14, methotrexate 40 mg/m(2) and 5-fluorouracil 500 mg/m(2) i.v. on Days 1 and 8 every 4 weeks. Both arms were scheduled for six cycles. RESULTS The median follow-up was 57 months. Eighteen of the 55 AC patients developed recurrence compared with 16 of the 69 CMF patients. The corresponding 5-year recurrence free survival rates were 64% and 78%, respectively (P = 0.12). The site of the first recurrence for AC patients was locoregional in 7%, distant in 22%, and combined in 4%. The corresponding data for the CMF arm were 4%, 16%, and 3%, respectively. Six AC patients died compared with 9 CMF patients. The corresponding 5-year survival rates were 90% and 86%, respectively (P = 0.96). More leukopenia (52%, mostly Grade 1-2) occurred in the CMF arm than in the AC arm (33%, P = 0.001), but no febrile episode was accompanied with leukopenia. CONCLUSIONS This study showed no difference between AC and CMF with respect to both disease free and overall survival rates in premenopausal women with axillary lymph node positive breast carcinoma.
Collapse
Affiliation(s)
- S M Bang
- Department of Internal Medicine and Surgery, Clinical Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Affiliation(s)
- S K Min
- Department of Surgery, Seoul National University College of Medicine, Seoul, South Korea
| | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Chung EJ, Choi SH, Shim YH, Bang YJ, Hur KC, Kim CW. Transforming growth factor-beta induces apoptosis in activated murine T cells through the activation of caspase 1-like protease. Cell Immunol 2000; 204:46-54. [PMID: 11006017 DOI: 10.1006/cimm.2000.1694] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Transforming growth factor-beta (TGF-beta) has been known as a potent immunosuppressive cytokine that can induce apoptosis in lymphoid cells. We established an IL-2-independent cell line, CTLL-2A, from murine T cell line CTLL-2. CTLL-2A expressed higher levels of CD95, CD69, and CD18 molecules than CTLL-2 did, suggesting a more activated state in CTLL-2A than in the CTLL-2 by phenotype. Exposing both CTLL-2 and CTLL-2A to TGF-beta results in differential apoptosis patterns defined by DNA fragmentation and plasma membrane alteration. Among the bcl-2 family members, bcl-2, bcl-w, and bcl-x(L) were also differently expressed in these two cell lines. In CTLL-2A, bcl-x(L) was amplified as a major anti-apoptotic molecule, and TGF-beta-induced cell death was more enhanced than in the original cell line. Caspase 1-like protease was activated by TGF-beta treatment and consequently it cleaved bcl-x(L) in CTLL-2A. TGF-beta-induced DNA fragmentation and cleavage of bcl-x(L) were inhibited by pretreatment with tetra peptide caspase 1 inhibitor, YVAD.cmk. These findings suggest that TGF-beta induces cell death in activated murine T cells through cleavage of bcl-x(L) via activated caspase 1-like protease, which may act as an important executor in that process.
Collapse
Affiliation(s)
- E J Chung
- Department of Pathology, Seoul National University College of Medicine, Seoul 110-799, Korea
| | | | | | | | | | | |
Collapse
|
46
|
Song SH, Jong HS, Choi HH, Kang SH, Ryu MH, Kim NK, Kim WH, Bang YJ. Methylation of specific CpG sites in the promoter region could significantly down-regulate p16(INK4a) expression in gastric adenocarcinoma. Int J Cancer 2000. [PMID: 10861481 DOI: 10.1002/1097-0215(20000715)87:2%3c236::aid-ijc14%3e3.0.co;2-m] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Silencing of p16(INK4a) by methylation of the CpG islands in the promoter region has been found to be an alternative mechanism of inactivation in several tumors. However, in gastric carcinoma, the relationship between methylation status and the transcriptional silencing of the p16 gene remains to be clarified. In this study, we investigated whether methylation of a few specific CpG sites in the promoter region could significantly down-regulate p16 activity in the tumorigenesis of gastric carcinoma. By Southern analysis and bisulfite-modified genomic sequencing of 9 gastric-carcinoma cell lines, we found that the 5 cell lines (55.5%) not expressing p16 mRNA had methylated CpG sites at the promoter region of p16. In addition, we analyzed the p16-protein expression of 28 primary gastric carcinomas and their normal counterparts by immunohistochemical staining (IHC) on paraffin sections. Loss of p16 expression was detected in 6 cases (22%). In 5 out of these 6 (83%), the actual p16 gene was inactivated by de novo methylation of the promoter sites. Taken together, these results suggest a strong correlation between de novo methylation of a few specific CpG sites and transcriptional silencing of the p16 gene in gastric carcinoma.
Collapse
Affiliation(s)
- S H Song
- Cancer Research Center, Seoul National University College of Medicine, Seoul, Republic of Korea
| | | | | | | | | | | | | | | |
Collapse
|
47
|
Song SH, Jong HS, Choi HH, Kang SH, Ryu MH, Kim NK, Kim WH, Bang YJ. Methylation of specific CpG sites in the promoter region could significantly down-regulate p16(INK4a) expression in gastric adenocarcinoma. Int J Cancer 2000. [PMID: 10861481 DOI: 10.1002/1097-0215(20000715)87:2<236::aid-ijc14>3.0.co;2-m] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Silencing of p16(INK4a) by methylation of the CpG islands in the promoter region has been found to be an alternative mechanism of inactivation in several tumors. However, in gastric carcinoma, the relationship between methylation status and the transcriptional silencing of the p16 gene remains to be clarified. In this study, we investigated whether methylation of a few specific CpG sites in the promoter region could significantly down-regulate p16 activity in the tumorigenesis of gastric carcinoma. By Southern analysis and bisulfite-modified genomic sequencing of 9 gastric-carcinoma cell lines, we found that the 5 cell lines (55.5%) not expressing p16 mRNA had methylated CpG sites at the promoter region of p16. In addition, we analyzed the p16-protein expression of 28 primary gastric carcinomas and their normal counterparts by immunohistochemical staining (IHC) on paraffin sections. Loss of p16 expression was detected in 6 cases (22%). In 5 out of these 6 (83%), the actual p16 gene was inactivated by de novo methylation of the promoter sites. Taken together, these results suggest a strong correlation between de novo methylation of a few specific CpG sites and transcriptional silencing of the p16 gene in gastric carcinoma.
Collapse
Affiliation(s)
- S H Song
- Cancer Research Center, Seoul National University College of Medicine, Seoul, Republic of Korea
| | | | | | | | | | | | | | | |
Collapse
|
48
|
Kang SH, Choi HH, Kim SG, Jong HS, Kim NK, Kim SJ, Bang YJ. Transcriptional inactivation of the tissue inhibitor of metalloproteinase-3 gene by dna hypermethylation of the 5'-CpG island in human gastric cancer cell lines. Int J Cancer 2000; 86:632-5. [PMID: 10797283 DOI: 10.1002/(sici)1097-0215(20000601)86:5<632::aid-ijc5>3.0.co;2-5] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
The tissue inhibitor of metalloproteinase-3 (TIMP-3), a recently cloned member of TIMP gene family, has been implicated in the negative regulation of tumor cell invasion and tumor growth. Down-regulation of this gene has been shown to occur in a mouse carcinogenesis model, suggesting that it might play a role in the tumor progression of some cancers. In this study, we used human gastric cancer cell lines to investigate whether TIMP-3 gene expression is suppressed in human gastric cancer. We examined whether aberrant DNA methylation of the 5'-CpG island of the TIMP-3 gene is involved in this cancer. Nine of 10 human gastric cancer cell lines completely lost TIMP-3 gene expression compared with normal samples. Southern blot analysis and bisulfite genomic sequencing revealed aberrant hypermethylation near the transcription-start site of the TIMP-3 gene in all cell lines lacking TIMP-3 expression. Treatment of these cell lines with the demethylating agent 5-aza-2'-deoxycytidine restored TIMP-3 gene expression. Our results suggest that the TIMP-3 gene is another early target of tumor-associated aberrant DNA methylation in human gastric carcinogenesis. Consequently, genetic silencing of TIMP-3 may lead to a more malignant and invasive phenotype in these cancer cells.
Collapse
Affiliation(s)
- S H Kang
- Cancer Research Center, Seoul National University Medical College, Seoul, Korea
| | | | | | | | | | | | | |
Collapse
|
49
|
Abstract
Recent observations suggest that immune response is involved in the development of pancreatitis. However, the exact pathogenesis underlying this immune-mediated response is still under debate. TGF-beta has been known to be an important regulating factor in maintaining immune homeostasis. To determine the role of TGF-beta in the initiation or progression of pancreatitis, TGF-beta signaling was inactivated in mouse pancreata by overexpressing a dominant-negative mutant form of TGF-beta type II receptor in the pancreas, under control of the pS2 mouse trefoil peptide promoter. Transgenic mice showed marked increases in MHC class II molecules and matrix metalloproteinase expression in pancreatic acinar cells. These mice also showed increased susceptibility to cerulein-induced pancreatitis. This pancreatitis was characterized by severe pancreatic edema, inflammatory cell infiltration, T- and B-cell hyperactivation, IgG-type autoantibodies against pancreatic acinar cells, and IgM-type autoantibodies against pancreatic ductal epithelial cells. Therefore, TGF-beta signaling seems to be essential either in maintaining the normal immune homeostasis and suppressing autoimmunity or in preserving the integrity of pancreatic acinar cells.
Collapse
Affiliation(s)
- K B Hahm
- Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, Bethesda, Maryland 20892, USA
| | | | | | | | | | | | | |
Collapse
|
50
|
Abstract
Signals from the TGF-betas are mediated by the TGF-beta receptors and their substrates, the Smad proteins. Inactivation of either of the two transmembrane serine/threonine kinases called the TGF-beta type I and type II receptors is now known to underlie a wide variety of human pathologies including, especially carcinogenesis. Numerous studies have now demonstrated that the TGF-beta receptor complex and its downstream signaling intermediates constitute a tumor suppressor pathway. We review here a specific pathway of mutational inactivation of the TGF-beta type II receptor resulting from microsatellite instability and demonstrate that, by contrast, the most common mechanism of loss of expression of the TGF-beta type II receptor involves transcriptional repression. This provides a new target for therapeutic intervention.
Collapse
Affiliation(s)
- S J Kim
- Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, Bethesda, MD 20892-5055, USA.
| | | | | | | |
Collapse
|